new report on EMIS describes well the company strategy and enormous prospects in the near future -https://seekingalpha.com/article/4171048-emispheres-solid-future - however, if what's in the report materializes, and EMIS gets royalties of only $110,000,000 a year then stock price should be considerably higher by the simple math of dividing $110,000,000 by the number of share outstanding fully diluted of 110,000,000 (Yahoo reports 60.85mm but this may not be fully diluted) then EPS=$1.00 - Give that a P/E multiple of 30 for being a biotech company then the price indeed should be considerably higher ($30) All these can be verified at the upcoming shareholder's meeting on the 17th of May, 2018. And only then we can have confidence at these numbers; until then this all speculative. We need a Wall Street Analyst report to sort these out since the company is silent and not reporting. Also, keep in mind this can be further multiplied as EMIS use their molecules as a platform to deliver other drugs orally. I have been in the stock for at least 15 years and have great confidence in the current management and board of directors. The best people produce the best things. I wish them all the best of luck and especially I wish the best to Mark Rashesky who rescued EMIS again and again - Yisshar Koach Mark May you and yours be blessed.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.